Newsfile Corp
20 Aug 2026, 02:48 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics faces a class action lawsuit alleging that the company failed to disclose that the FDA had not agreed to changes in the statistical analysis plan for its Deramiocel clinical data. — Allegations of regulatory misalignment and lack of FDA agreement on clinical data analysis create significant uncertainty regarding the approval of a primary product candidate.
-0.70The lawsuit claims there is a substantial risk that the FDA could conclude the clinical results for Deramiocel do not provide substantial evidence of effectiveness for treating Duchenne muscular dystrophy. — Direct questioning of the efficacy of the core pipeline asset increases the risk of regulatory rejection, which is a binary catalyst for biotech valuations.
-0.60Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to move for lead plaintiff status in the litigation. — While primarily a procedural legal deadline, the existence of an active class action can create a lingering overhang on the stock price.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a securities class action lawsuit alleging materially false statements regarding clinical data and FDA approval risks.
The company is mentioned as being subject to a securities class action lawsuit.
The company is mentioned in the context of a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
